Ana-Marija Milenković-Grišić

6PUBLICATIONS
11CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyToxicology (incl. clinical toxicology)Radiation therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 12, 2024
Model-informed Evidence for Clinical Non-inferiority of Every-2-Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer.

Ana-Marija Milenković-Grišić, Siobhán Hayes, Colm Farrell

|Dec 13, 2023
Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non-small cell lung cancer based on bintrafusp alfa trials.

Ana-Marija Milenković-Grišić, Nadia Terranova, Diane R Mould

|May 11, 2023
A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancer.

Han Liu, Ana-Marija Milenković-Grišić, Sreenath M Krishnan

|Dec 20, 2022
Variable or variate? A conundrum in pharmacometrics exposure-response models.

Ana-Marija Grisic, Karthik Venkatakrishnan, Jonathan French

|Mar 14, 2022
Pharmacometrics Golems: Exposure-Response Models in Oncology.

Akash Khandelwal, Ana-Marija Grisic, Jonathan French

|Nov 13, 2020
Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management.

Ana-Marija Grisic, Alexander Eser, Wilhelm Huisinga

Pageof 1

Frequent Collaborators

4 joint publications

Akash Khandelwal

3 joint publications

Karthik Venkatakrishnan

2 joint publications

Jonathan French

1 joint publications

Han Liu